Sotio begins Ph II for second-line ovarian cancer candidate

Sotio a.s. (Prague, Czech Republic) began the open-label Phase II SOV06 trial evaluating immunotherapy candidate DCVAC/OvCa as a second-line treatment in combination with standard of care chemotherapy in 30 patients with relapsed platinum-sensitive epithelial ovarian carcinoma.

The trial will evaluate progression-free survival (PFS) as its primary endpoint. Secondary endpoints include overall survival (OS), objective response rate (ORR) and CA-125 and immunological responses...